AU2018279105A1 - Antibody conjugates of immune-modulatory compounds and uses thereof - Google Patents

Antibody conjugates of immune-modulatory compounds and uses thereof Download PDF

Info

Publication number
AU2018279105A1
AU2018279105A1 AU2018279105A AU2018279105A AU2018279105A1 AU 2018279105 A1 AU2018279105 A1 AU 2018279105A1 AU 2018279105 A AU2018279105 A AU 2018279105A AU 2018279105 A AU2018279105 A AU 2018279105A AU 2018279105 A1 AU2018279105 A1 AU 2018279105A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
sequence
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018279105A
Other languages
English (en)
Inventor
Peter Robert Baum
Craig Alan Coburn
Badreddin EDRIS
Valerie Odegard
Peter Armstrong Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARS Pharmaceuticals Inc
Original Assignee
Silverback Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silverback Therapeutics Inc filed Critical Silverback Therapeutics Inc
Publication of AU2018279105A1 publication Critical patent/AU2018279105A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2018279105A 2017-06-07 2018-06-07 Antibody conjugates of immune-modulatory compounds and uses thereof Abandoned AU2018279105A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762516638P 2017-06-07 2017-06-07
US62/516,638 2017-06-07
PCT/US2018/036554 WO2018227018A1 (en) 2017-06-07 2018-06-07 Antibody conjugates of immune-modulatory compounds and uses thereof

Publications (1)

Publication Number Publication Date
AU2018279105A1 true AU2018279105A1 (en) 2019-12-19

Family

ID=64567206

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018279105A Abandoned AU2018279105A1 (en) 2017-06-07 2018-06-07 Antibody conjugates of immune-modulatory compounds and uses thereof

Country Status (7)

Country Link
US (1) US20200199247A1 (cg-RX-API-DMAC10.html)
EP (1) EP3634485A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020523319A (cg-RX-API-DMAC10.html)
CN (1) CN110891605A (cg-RX-API-DMAC10.html)
AU (1) AU2018279105A1 (cg-RX-API-DMAC10.html)
CA (1) CA3065852A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018227018A1 (cg-RX-API-DMAC10.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
BR112020023926A2 (pt) * 2018-05-25 2021-02-17 Silverback Therapeutics, Inc. compostos de amino-pirazinocarboxamida, conjugados e usos dos mesmos
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CA3139274A1 (en) * 2019-05-10 2020-11-19 Lyvgen Biopharma Co., Ltd. Humanized anti-cd137 antibodies and uses thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP3999544A4 (en) * 2019-07-19 2023-08-09 Wuxi Xdc Singapore Private Limited POLYPEPTIDE COMPLEX FOR CONJUGATION AND ITS USE
EP4008730A4 (en) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
WO2021102332A1 (en) * 2019-11-22 2021-05-27 Silverback Therapeutics, Inc. Tgfbetar2 inhibitor-lrrc15 antibody conjugates and uses thereof
EP4041769A1 (en) * 2019-12-12 2022-08-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Antibody-drug conjugates specific for cd276 and uses thereof
CN115052663B (zh) * 2020-01-08 2026-06-09 辛瑟斯治疗股份有限公司 Alk5抑制剂缀合物及其用途
TWI854088B (zh) * 2020-01-27 2024-09-01 英商梅迪繆思有限公司 用於治療腎臟疾病之抗αvβ8整聯蛋白抗體
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN115379848A (zh) * 2020-04-01 2022-11-22 加利福尼亚大学董事会 靶向间充质干细胞衍生的癌细胞和间充质干细胞相关疾病的免疫治疗诊断剂
CN113509557A (zh) * 2020-04-09 2021-10-19 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
WO2021231922A1 (en) * 2020-05-14 2021-11-18 The General Hospital Corporation Agonistic tumor necrosis factor receptor superfamily polypeptides
WO2021243136A2 (en) * 2020-05-29 2021-12-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods and compositions for treating, preventing the onset and/or slowing progression of osteoarthritis
EP4157883A4 (en) * 2020-06-02 2024-12-04 Children's Medical Center Corporation NANOBODY CONJUGATES (VHH) AND THEIR USES
CN117083079A (zh) * 2020-06-02 2023-11-17 儿童医学中心公司 纳米抗体(vhh)缀合物及其用途
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
KR102506295B1 (ko) * 2020-08-28 2023-03-08 국립암센터 디그옥시제닌에 대한 인간화 항체 및 이의 용도
CN114146095A (zh) * 2020-09-07 2022-03-08 是光隽恒(北京)生物科技有限公司 用于组织损伤修复的组合物及其制备方法和用途
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
GB202104935D0 (en) * 2021-04-07 2021-05-19 Hummingbird Bioscience Holdings Pte Ltd BCMA/TACI antigen-binding molecules
WO2022109105A1 (en) * 2020-11-18 2022-05-27 Pandion Operations, Inc. Madcam targeted therapeutics and uses thereof
AU2022254042A1 (en) * 2021-04-07 2023-09-14 Mythic Therapeutics, Inc. Antigen-binding protein constructs and antibodies and uses thereof
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
JP2024526259A (ja) 2021-07-02 2024-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗protac抗体および複合体
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US20250043005A1 (en) * 2021-12-09 2025-02-06 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody-cytokine fusion proteins and applications thereof
EP4458830A4 (en) * 2021-12-30 2025-12-03 Sichuan Kelun Biotech Biopharmaceutical Co Ltd TRICYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS USE
CA3262796A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific Polypeptides and Their Uses
CN120417934A (zh) * 2022-12-23 2025-08-01 基因泰克公司 Cereblon降解剂缀合物及其用途
IL321713A (en) 2022-12-27 2025-08-01 Merck Patent Gmbh Anti-PROTAC VHH antibodies and complexes
WO2024200987A1 (en) * 2023-03-31 2024-10-03 Avacta Life Sciences Limited Tnfr2 binding polypeptides and methods of use
FR3147278A1 (fr) * 2023-03-31 2024-10-04 Avacta Life Sciences Limited Polypeptides de liaison au tnfr2 et procedes d'utilisation
FR3147292A1 (fr) * 2023-03-31 2024-10-04 Affyxell Therapeutics Co., Ltd. Cellules genetiquement modifiees dans lesquelles un acide nucleique codant pour des variantes de la proteine stefine a se liant specifiquement au tnfr2 ou une proteine de fusion comprenant celle-ci a ete introduite, et leurs utilisations
KR20260023524A (ko) * 2023-05-18 2026-02-20 파이어플라이 바이오, 인크. 이소인돌리논-글루타르이미드 항체 접합체 및 이의 용도
WO2024243545A1 (en) * 2023-05-24 2024-11-28 President And Fellows Of Harvard College Compositions targeting endothelial cells and uses thereof
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
TW202547866A (zh) 2024-01-10 2025-12-16 丹麥商珍美寶股份有限公司 Slitrk6結合劑、其共軛物及使用彼之方法
WO2025163120A1 (en) * 2024-02-01 2025-08-07 Adcytherix Sas ANTIBODY-DRUG CONJUGATES COMPRISING AN ANTI-INTEGRIN ΑVβ6 BINDING ANTIBODY
EP4595981A1 (en) * 2024-02-01 2025-08-06 Jack Elands Antibody-drug conjugates comprising an anti-integrin v 6 binding antibody
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025216667A1 (en) * 2024-04-12 2025-10-16 Joint Stock Company «Biocad» Monoclonal antibody that specifically binds to bdca-2
WO2026093513A1 (en) 2024-10-31 2026-05-07 Sotio Biotech A.S. Anti-lrrc15 antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
KR101281501B1 (ko) * 2004-12-09 2013-07-15 얀센 바이오테크 인코포레이티드 항인테그린 면역 컨쥬게이트, 방법 및 용도
WO2011040973A2 (en) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
WO2011040972A1 (en) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
EP2608804A4 (en) * 2010-08-27 2015-03-11 Univ Miami TREATMENT OF KIDNEY DISEASES
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
CN104053513B (zh) * 2012-01-26 2016-05-11 株式会社万 弯曲中空管的制造方法
DK3151865T3 (da) * 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
EP3383909B1 (en) * 2015-11-30 2020-06-17 AbbVie Inc. Anti-human lrrc15 antibody drug conjugates and methods for their use
JP2019501124A (ja) * 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗huLRRC15抗体薬物コンジュゲート及びその使用方法
US20210154188A1 (en) * 2018-04-02 2021-05-27 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
BR112020023926A2 (pt) * 2018-05-25 2021-02-17 Silverback Therapeutics, Inc. compostos de amino-pirazinocarboxamida, conjugados e usos dos mesmos

Also Published As

Publication number Publication date
CN110891605A (zh) 2020-03-17
WO2018227018A1 (en) 2018-12-13
EP3634485A4 (en) 2021-07-21
JP2020523319A (ja) 2020-08-06
US20200199247A1 (en) 2020-06-25
EP3634485A1 (en) 2020-04-15
CA3065852A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
US20200199247A1 (en) Antibody conjugates of immune-modulatory compounds and uses thereof
EP3595668B1 (en) Benzazepine compounds, conjugates, and uses thereof
EP3634401A1 (en) Antibody construct conjugates
US20220362396A1 (en) Amino-pyrazinecarboxamide compounds, conjugates, and uses thereof
EP3999501A1 (en) Alk5 inhibitors, conjugates, and uses thereof
JP2022500404A (ja) 置換ベンゾアゼピン化合物、そのコンジュゲートおよび使用
US20190144558A1 (en) Compositions and methods for the depletion of cd117+ cells
AU2018385693A1 (en) Antibody construct-drug conjugate for the treatment of hepatitis
WO2019195278A1 (en) Alk5 inhibitors, conjugates, and uses thereof
WO2018144955A1 (en) Construct-peptide compositions and methods of use thereof
KR20210061995A (ko) Adam9를 표적으로 하는 면역콘쥬게이트 및 이를 이용하는 방법들
CA3131104A1 (en) Cyclic amino-pyrazinecarboxamide compounds and uses thereof
WO2022006340A1 (en) Alk5 inhibitors, conjugates, and uses thereof
WO2022076905A1 (en) Alk5 inhibitors, conjugates, and uses thereof
GB2552041A (en) Compositions of antibody construct-agonist conjugates and methods thereof
HK40021778B (en) Benzazepine compounds, conjugates, and uses thereof
HK40021778A (en) Benzazepine compounds, conjugates, and uses thereof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period